Bedaquiline’s clinical efficacy in the management of drug-resistant tuberculosis

This review article comprehensively examines the clinical efficacy of bedaquiline in the management of drug-resistant tuberculosis (TB). Drug-resistant TB poses a significant challenge to global health systems, necessitating innovative therapeutic approaches. Bedaquiline, a novel anti-TB medication,...

Full description

Saved in:
Bibliographic Details
Main Authors: Makkad, Saniya, Jirvankar, Pranita, Agarwal, Rishabh, Tiwari, Shweta, Munshi, Aniket
Format: Conference Proceeding
Language:English
Subjects:
Effectiveness
Public health
Tuberculosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review article comprehensively examines the clinical efficacy of bedaquiline in the management of drug-resistant tuberculosis (TB). Drug-resistant TB poses a significant challenge to global health systems, necessitating innovative therapeutic approaches. Bedaquiline, a novel anti-TB medication, has emerged as a promising solution against multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). This article delves into the mechanisms of action, pharmacokinetic properties, and pharmacodynamic characteristics of bedaquiline. It explores clinical trials and real-world studies, providing insights into its effectiveness, adverse events, and impact on patient outcomes. The review sheds light on the role of bedaquiline in combination therapies, its potential to address treatment gaps, and its implications in public health efforts to combat drug-resistant TB. By evaluating the existing evidence, this article offers a comprehensive overview of bedaquiline’s contributions and challenges in tackling drug-resistant TB.
ISSN:0094-243X
1551-7616
DOI:10.1063/5.0240425